Results for tag: "Cytodyn"

CytoDyn is a biotechnology company focused on the development of novel therapies for cancer and other diseases. The company's lead product, leronlimab, is a CCR5 antagonist that has been studied in multiple clinical trials for the treatment of various cancers, including metastatic triple-negative breast cancer, non-small cell lung cancer, and metastatic colorectal cancer. In addition, leronlimab has been studied in combination with other therapies, such as chemotherapy and immunotherapy, to improve outcomes in cancer patients. CytoDyn is also developing leronlimab for the treatment of HIV and other infectious diseases. The company is currently conducting a Phase 3 clinical trial of leronlimab for the treatment of HIV, and has also completed a Phase 2 clinical trial of leronlimab for the treatment of COVID-19. The oncology drug market is a rapidly growing sector of the pharmaceutical industry, with a wide range of products and treatments available. CytoDyn is one of many companies in the oncology drug market, which includes large pharmaceutical companies such as Merck, Pfizer, and Bristol-Myers Squibb, as well as smaller biotechnology companies such as ImmunoGen, Incyte, and Tesaro. Show Less Read more